Home > Hepatitis C screening. National clinical guideline no. 15.

Department of Health. (2017) Hepatitis C screening. National clinical guideline no. 15. Dublin: Department of Health.

[img]
Preview
PDF (Hepatitis C gudelines - full report) - Published Version
1MB
[img]
Preview
PDF (Hepatitis C gudelines - summary) - Supplemental Material
837kB

External website: http://health.gov.ie/national-patient-safety-offic...

This Summary National Clinical Guideline is relevant to all healthcare professionals, healthcare managers and policy makers working with those at increased risk of hepatitis C virus (HCV) infection. The guideline will also be of value to both statutory and voluntary bodies providing services to those groups at increased risk of HCV infection. It may also be used by those with HCV or in a risk group for HCV and by members of the public.

Hepatitis C virus (HCV) is a major cause of liver disease worldwide. Globally, it is estimated that there are 115 million people who have had HCV infection, and 80 million with chronic infection. Transmission of HCV occurs through contact with the blood of an infected person. Risk factors for HCV differ globally. In developed countries like Ireland, injecting drug use (IDU) is the major risk factor. (3.1.4 People who use unprescribed or illicit drugs - page 15)

Repository Staff Only: item control page